XML 27 R17.htm IDEA: XBRL DOCUMENT
v3.23.2

GOODWILL AND OTHER INTANGIBLE ASSETS (Notes) | 9 Months Ended
--- | ---
Jul. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS | GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the nine months ended July 31, 2023:
| Life Sciences and Applied Markets |  | Diagnostics and Genomics |  | Agilent CrossLab |  | Total
| (in millions)
Goodwill as of October 31, 2022 | $ | 1,743 |  |  | $ | 1,953 |  |  | $ | 256 |  |  | $ | 3,952 |
Foreign currency translation impact | 11 |  |  | 1 |  |  | 5 |  |  | 17 |
Goodwill arising from acquisitions and adjustments | — |  |  | 15 |  |  | — |  |  | 15 |
Goodwill as of July 31, 2023 | $ | 1,754 |  |  | $ | 1,969 |  |  | $ | 261 |  |  | $ | 3,984 |
The component parts of other intangible assets as of October 31, 2022 and July 31, 2023 are shown in the table below:
| Other Intangible Assets
| Gross Carrying Amount |  | Accumulated Amortization |  | Net Book Value
| (in millions)
As of October 31, 2022 |  |  |  |  |
Purchased technology | $ | 1,733 |  |  | $ | 1,068 |  |  | $ | 665 |
Trademark/Tradename | 196 |  |  | 148 |  |  | 48 |
Customer relationships | 180 |  |  | 105 |  |  | 75 |
Backlog | 8 |  |  | 8 |  |  | — |
Third-party technology and licenses | 32 |  |  | 9 |  |  | 23 |
Total amortizable intangible assets | 2,149 |  |  | 1,338 |  |  | 811 |
In-Process R&D | 10 |  |  | — |  |  | 10 |
Total | $ | 2,159 |  |  | $ | 1,338 |  |  | $ | 821 |
As of July 31, 2023 |  |  |  |  |
Purchased technology | $ | 1,470 |  |  | $ | 1,078 |  |  | $ | 392 |
Trademark/Tradename | 196 |  |  | 159 |  |  | 37 |
Customer relationships | 156 |  |  | 114 |  |  | 42 |
Third-party technology and licenses | 33 |  |  | 12 |  |  | 21 |
Total amortizable intangible assets | 1,855 |  |  | 1,363 |  |  | 492 |
In-Process R&D | 10 |  |  | — |  |  | 10 |
Total | $ | 1,865 |  |  | $ | 1,363 |  |  | $ | 502 |
During the nine months ended July 31, 2023, we recorded additions of $15 million to goodwill and $49 million to other intangible assets in our diagnostics and genomics and life sciences and applied markets segments related to two acquisitions. During the nine months ended July 31, 2023, other intangible assets in total increased $3 million due to the impact of foreign currency translation. In general, for U.S. federal tax purposes, goodwill from asset purchases is amortizable; however, any goodwill created as part of a stock acquisition is not deductible. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. During the three and nine months ended July 31, 2023 and 2022 we did not identify any triggering events or circumstances which would indicate an impairment of goodwill or indefinite-lived intangible assets. During the three and nine months ended July 31, 2023, we recorded an impairment of finite-lived intangible assets of $258 million related to the shutdown of our Resolution Bioscience business in our diagnostics and genomics segment. Of the $258 million, $249 million was recorded in cost of sales and $9 million was recorded in selling, general and administrative expenses on our condensed consolidated statement of operations in both the three and nine months ended July 31, 2023. Amortization expense of intangible assets was $39 million and $113 million for the three and nine months ended July 31, 2023, respectively. Amortization expense of intangible assets was $48 million and $150 million for the three and nine months ended July 31, 2022, respectively. Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2023 and for each of the next five fiscal years and thereafter is estimated below:
Estimated future amortization expense: |
(in millions) |
Remainder of 2023 | $ | 27 |
2024 | $ | 100 |
2025 | $ | 83 |
2026 | $ | 53 |
2027 | $ | 52 |
2028 | $ | 45 |
Thereafter | $ | 132 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration